Posted on 10 August 2015
An interview with Richard Brudnick, Senior VP, Corporate Development, Biogen De-risking has evolved from literature searches to the cultivation of many wide-ranging relationships throughout the life sciences strata, according to Richard Brudnick, Senior VP, Corporate Development at Biogen. In a recent interview, Brudnick outlined key strategies to accessing innovation and “de-risking” risk through collaboration.
Tags: big biotech, big pharma, biotech, partnering, pharma
Posted on 15 May 2015
Sorrento Therapeutics agreed to sell its drug candidate Cynviloq (paclitaxel nanoparticle polymeric micelle) for up to $1.3 billion to NantPharma.
Tags: Nantpharma, Sorrento
Posted on 13 May 2015
Agilis Biotherapeutics has entered into an exclusive worldwide license agreement with the University of South Florida for the treatment of using gene therapy technology developed by Edwin Weeber, PhD, Director of the Neurobiology of Learning and Memory and Chief Scientific Officer at the USF Health Byrd Alzheimer’s Research Institute at the University of South Florida, more »
Tags: Agilis, gene therapy, University of South Florida
Posted on 12 May 2015
Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company.
Tags: AM-Pharma, Pfizer
Posted on 06 May 2015
EMD Serono has begun co-promoting Pfizer’s anaplastic lymphoma kinase (ALK) inhibitor XALKORI (crizotinib) as part of its global strategic alliance with Pfizer.
Tags: EMD Serono, Pfizer
Posted on 05 May 2015
23andMe announced the launch of the Lupus Research Study in collaboration with Pfizer.
Tags: 23andMe, Pfizer
Posted on 05 May 2015
Bayer HealthCare has entered into an exclusive license agreement with Isis Pharmaceuticals on ISIS-FXIRx
Tags: Bayer, big pharma, partnering
Posted on 30 April 2015
4D Molecular Therapeutics announced a collaboration and license agreement with Roche to discover and develop optimized next-generation AAV vectors
Tags: big pharma, partnering, Roche
Posted on 28 April 2015
Innate Pharma has signed a co-development and commercialization agreement with AstraZeneca
Tags: AstraZeneca, big pharma, partnering
Posted on 28 April 2015
Celgene has entered into a strategic collaboration with MedImmune to develop and commercialize an anti-PD-L1 inhibitor, MEDI4736, for hematologic malignancies
Tags: AstraZeneca, big pharma, Celgene